Infectious Diseases

Back to articles

Emergency use of peramivir approved for H1N1 influenza

KEY POINT

FDA has issued an emergency use authorization for I.V. peramivir, an unapproved investigational neuraminidase inhibitor, for the treatment of specific adult and pediatric patients with suspected or laboratory-confirmed H1N1 influenza. Peramivir is authorized for use in patients not responding to either oral or inhaled antiviral therapy or when drug delivery by a route other than I.V. is not expected to be dependable or feasible.